Entrar/Registro  
INICIO ENGLISH
 
Revista Mexicana de Neurociencia
   
MENÚ

Contenido por año, Vol. y Num.

Índice de este artículo

Información General

Instrucciones para Autores

Mensajes al Editor

Directorio






>Revistas >Revista Mexicana de Neurociencia >Año 2007, No. 5


Cedeno-Laurent F, Berg E, Trujillo JR
Complicaciones neurológicas en pacientes coinfectados con el VIH-1 y el Virus de la Hepatitis C
Rev Mex Neuroci 2007; 8 (5)

Idioma: Español
Referencias bibliográficas: 38
Paginas: 512-515
Archivo PDF: 71.68 Kb.


Texto completo




RESUMEN

Nueva evidencia está emergiendo, apoyando un papel importante del virus de la hepatitis C (VHC) como agente causal de enfermedad neurológica en los pacientes con VIH-1/SIDA. Las manifestaciones neurológicas asociadas a la coinfección representan motivos frecuentes de consulta en las unidades neurológicas y psiquiátricas. Déficits motores, verbales, de aprendizaje y atención, se reconocen con mayor frecuencia, no sólo como causa de la encefalopatía metabólica, sino como producto de la infección por el VHC a células del sistema nervioso central (SNC). En esta revisión, describimos las características principales de la coinfección, enfatizando la epidemiología, la biología molecular y la patogénesis de la enfermedad neurológica asociada a la coinfección.


Palabras clave: SIDA, neurotropismo, encefalopatía, demencia.


REFERENCIAS

  1. Palella FJ Jr., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338(13): 853-60.

  2. Lewden C, et al. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol 2005; 34(1): 121-30.

  3. Salmon-Ceron D, et al. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol 2005; 42(6): 799-805.

  4. Rosenthal E, et al. Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study). Aids 2003; 17(12): 1803-9.

  5. Bica I, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32(3): 492-7.

  6. De Francesco R, Migliaccio G. Challenges and successes in developing new therapies for hepatitis C. Nature 2005; 436(7053): 953-60.

  7. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology 2002; 36(5 Suppl 1): S21-9.

  8. Seeff LB. Natural history of hepatitis C. Am J Med 1999; 107(6B): 10S-15S.

  9. Forton DM, et al. A review of cognitive impairment and cerebral metabolite abnormalities in patients with hepatitis C infection. Aids 2005; 19 Suppl 3: S53-63.

  10. Laskus T, et al. Emerging evidence of hepatitis C virus neuroinvasion. Aids 2005; 19 Suppl 3: S140-4.

  11. Weiss JJ, Gorman JM. Psychiatric behavioral aspects of comanagement of hepatitis C virus and HIV. Curr HIV/AIDS Rep 2006; 3(4): 176-81.

  12. Cherner M, et al. Hepatitis C augments cognitive deficits associated with HIV infection and methamphetamine. Neurology 2005. 64(8): 1343-7.

  13. Sulkowski MS, Thomas DJ, Hepatitis C in the HIV-Infected Person. Ann Intern Med 2003; 138(3): 197-207.

  14. Hagan H, Thiede H, DC. Des Jarlais, HIV/hepatitis C virus co-infection in drug users: risk behavior and prevention. Aids 2005; 19(Suppl 3): S199-207.

  15. Terrault NA, Sexual activity as a risk factor for hepatitis C. Hepatology 2002; 36(5 Suppl 1): S99-105.

  16. Wyld R, et al. Absence of hepatitis C virus transmission but frequent transmission of HIV-1 from sexual contact with doubly-infected individuals. J Infect 1997; 35(2): 163-6.

  17. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345(1): 41-52.

  18. Thomas DL, et al. Perinatal transmission of hepatitis C virus from human immunodeficiency virus type 1-infected mothers. Women and Infants Transmission Study. J Infect Dis 1998; 177(6): 1480-8.

  19. Yeung LT, King SM, Roberts EA. Mother-to-infant transmission of hepatitis C virus. Hepatology 2001; 34(2): 223-9.

  20. Mast EE, et al. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. J Infect Dis 2005; 192(11): 1880-9.

  21. Thomas DL, et al. Sexual transmission of hepatitis C virus among patients attending sexually transmitted diseases clinics in Baltimore - an analysis of 309 sex partnerships-. J Infect Dis 1995; 171(4): 768- 75.

  22. Filippini P, et al. Does HIV infection favor the sexual transmission of hepatitis C? Sex Transm Dis 2001; 28(12): 725-9.

  23. Bini EJ, et al. National multicenter study of HIV testing and HIV seropositivity in patients with chronic hepatitis C virus infection. J Clin Gastroenterol 2006; 40(8): 732-9.

  24. Rosenberg SD, et al. Hepatitis C virus and HIV co-infection in people with severe mental illness and substance use disorders. Aids 2005; 19(Suppl 3): S26-33.

  25. Nyamathi AM, et al. Hepatitis C virus infection, substance use and mental illness among homeless youth: a review. Aids 2005; 19(Suppl 3): S34-40.

  26. Weinbaum CM, Sabin KM, Santibanez SS. Hepatitis B, hepatitis C, and HIV in correctional populations: a review of epidemiology and prevention. Aids 2005; 19(Suppl 3): S41-6.

  27. Des Jarlais DC, et al. Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990-2001. Aids 2005; 19(Suppl 3): S20-5.

  28. Rodriguez CM, Marques LF, Touze G. HIV and injection drug use in Latin America. Aids 2002; 16 (Suppl 3): S34-41.

  29. Perelson AS, et al. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span and viral generation time. Science 1996; 271(5255): 1582-6.

  30. Neumann AU, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282(5386): 103- 7.

  31. Laskus T, et al. Hepatitis C virus in lymphoid cells of patients coinfected with human immunodeficiency virus type 1: evidence of active replication in monocytes/macrophages and lymphocytes. J Infect Dis 2000; 181(2): 442-8.

  32. Forton DM, Taylor-Robinson SD, Thomas HC. Central nervous system changes in hepatitis C virus infection. Eur J Gastroenterol Hepatol 2006; 18(4): 333-8.

  33. Adair DM, et al. Differential display analysis of gene expression in brains from hepatitis C-infected patients. Aids 2005; 19(Suppl 3): S145-50.

  34. Trujillo JR, et al. Neurologic manifestations of AIDS: a comparative study of two populations from Mexico and the United States. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 8(1): 23-9.

  35. Trujillo JR, et al. High levels of anti-HIV-1 envelope antibodies in cerebrospinal fluid as compared to serum from patients with AIDS dementia complex. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 12(1): 19-25.

  36. Ritola K, et al. Increased human immunodeficiency virus type 1 (HIV- 1) env compartmentalization in the presence of HIV-1-associated dementia. J Virol 2005; 79(16): 10830-4.

  37. McArthur JC, Brew BJ, Nath A. Neurological complications of HIV infection. Lancet Neurol 2005; 4(9): 543-55.

  38. Kontorinis N, Agarwal K, Dieterich DT, Treatment of hepatitis C virus in HIV patients: a review. Aids 2005; 19(Suppl 3): S166-73.



>Revistas >Revista Mexicana de Neurociencia >Año2007, No. 5
 

· Indice de Publicaciones 
· ligas de Interes 






       
Derechos Resevados 2019